TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts

Related Keywords

Tokyo , Japan , United Kingdom , Brazil , Hong Kong , Cambridge , Cambridgeshire , Taiwan , Russia , Switzerland , Israel , Massachusetts , United States , Singapore , India , China , Australia , Canada , South Korea , Saudi Arabia , Great Britain , Chuck Triano , Christophera Viehbacher , Linkedinand Facebook , Tsujim Protofibrils , Jack Cox , Haruo Naito , Julie Edelman , Drug Administration , European Union , Nasdaq , United Nations Sustainable Development Goals Sdgs , Linkedin , Investor Relations Department , Exchange Commission , Eisai Co Ltd , National Institutes Of Health , Youtube , Communications Department , Washington University School Of Medicine , Eisai Europe Ltd , National Institute On , Alzheimer Clinical Trial Consortium , Public Relations Department , Alzheimer Network Trials Unit , Facebook , Eisai Inc , Biogen Inc , Supplemental Biologics License Application , Prescription Drug User Fee Act , Fast Track , Antithrombotic Medication , Risk Factors , Intracerebral Hemorrhage , Dose Management , Prescribing Informationfor , Clinical Dementia Rating Sum , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Corporate Concept , United Nations Sustainable Development Goals , Important Targets , Disease Modifying Approach , Intj Mol , Accelerated Approval , Japan Available , South Korea Available , Early Alzheimer , New England Journal , Ihr Portfolio ,